- Home
- TRMB vs INCY Comparison
TRMB vs INCY Comparison
Compare TRMB & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMB
- INCY
- Stock Information
- Founded
- TRMB 1978
- INCY 1991
- Country
- TRMB United States
- INCY United States
- Employees
- TRMB N/A
- INCY N/A
- Industry
- TRMB Industrial Machinery/Components
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TRMB Industrials
- INCY Health Care
- Exchange
- TRMB Nasdaq
- INCY Nasdaq
- Market Cap
- TRMB 19.3B
- INCY 17.0B
- IPO Year
- TRMB 1990
- INCY 1993
- Fundamental
- Price
- TRMB $79.55
- INCY $85.33
- Analyst Decision
- TRMB Buy
- INCY Buy
- Analyst Count
- TRMB 7
- INCY 20
- Target Price
- TRMB $92.00
- INCY $80.67
- AVG Volume (30 Days)
- TRMB 1.4M
- INCY 1.8M
- Earning Date
- TRMB 11-05-2025
- INCY 10-28-2025
- Dividend Yield
- TRMB N/A
- INCY N/A
- EPS Growth
- TRMB N/A
- INCY 900.04
- EPS
- TRMB 1.18
- INCY 4.37
- Revenue
- TRMB $3,575,500,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- TRMB N/A
- INCY $16.41
- Revenue Next Year
- TRMB $6.82
- INCY $10.86
- P/E Ratio
- TRMB $68.58
- INCY $19.55
- Revenue Growth
- TRMB N/A
- INCY 18.87
- 52 Week Low
- TRMB $52.91
- INCY $53.56
- 52 Week High
- TRMB $87.50
- INCY $88.66
- Technical
- Relative Strength Index (RSI)
- TRMB 44.64
- INCY 53.03
- Support Level
- TRMB $79.07
- INCY $85.18
- Resistance Level
- TRMB $81.38
- INCY $88.27
- Average True Range (ATR)
- TRMB 1.62
- INCY 1.93
- MACD
- TRMB -0.13
- INCY -0.13
- Stochastic Oscillator
- TRMB 24.32
- INCY 55.79
About TRMB Trimble Inc.
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.